Details for Patent: 5,693,626
✉ Email this page to a colleague
Title: | Tetrahydrofuran antifungals |
Abstract: | A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two phosphate ester groups (e.g., a phosphate ester convertible in vivo into a hydroxy group) thereof or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed. |
Inventor(s): | Saksena; Anil K. (Upper Montclair, NJ), Girijavallabhan; Viyyoor M. (Parsippany, NJ), Lovey; Raymond G. (West Caldwell, NJ), Pike; Russell E. (Stanhope, NJ), Wang; Haiyan (Dayton, NJ), Liu; Yi-Tsung (Morris Township, NJ), Ganguly; Ashit K. (Upper Montclair, NJ), Bennett; Frank (Piscataway, NJ) |
Assignee: | Schering Corporation (Kenilworth, NJ) |
Filing Date: | Jun 02, 1995 |
Application Number: | 08/459,145 |
Claims: | 1. A compound represented by the formula I ##STR109## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.4 to C.sub.5) alkyl group substituted by an ester or an ether group or a pharmaceutically acceptable salt thereof. 2. A compound of claim 1 wherein R.sub.1 is a C.sub.4 -or C.sub.5 -alkyl group selected from: --H(C.sub.2 H.sub.5)H(R.sub.4)CH.sub.3, --H(C.sub.2 H.sub.5)CH.sub.2 CH.sub.2 R.sub.4, --(CH.sub.2).sub.2 H(R.sub.4)C.sub.2 H.sub.5, --H(CH.sub.3)H(R.sub.4)CH.sub.3, --H(C.sub.2 H.sub.5)CH.sub.2 R.sub.4 and --H(CH.sub.3)CH.sub.2 Ch.sub.2 R.sub.4 wherein R.sub.4 is an ester group or an ether group and the carbons with the asterisk(*) have the R or S absolute configuration or a pharmaceutically acceptable salt thereof. 3. A compound represented by formula III ##STR110## wherein R.sub.5 is ##STR111## wherein R.sub.12 is an ester group or an ether group or a pharmaceutically acceptable salt thereof. 4. A compound represented by the formula IV ##STR112## wherein R.sub.9 =--H(C.sub.2 H.sub.5)CH(R.sub.6)CH.sub.3 or --H(CH.sub.3)CH(R.sub.6)CH.sub.3 wherein R.sub.6 is an ester group or an ether group. 5. A compound of claim 4 which is ##STR113## or a pharmaceutically acceptable salt thereof. 6. A compound of claim 1 wherein the ester group is a polyether ester, a phosphate ester, a heterocyclic ester, an alkanoate ester, an alkenoate ester, an amino acid acid ester, an acid ester, or a sulfate ester. 7. A compound of claim 1 wherein R.sub.1 is a straight or branched chain (C.sub.4 -C.sub.5) alkyl group substituted by an ester group. 8. A compound of claim 4 wherein the ester group is a polyether ester, a phosphate ester, a heterocyclic ester, an alkanoate ester, an alkenoate ester, an amino acid acid ester, an acid ester, or a sulfate ester. 9. A pharmaceutical composition for treating or preventing fungal infection comprising an antifungally effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier therefor. 10. A method of treating and/or preventing fungal infections in a mammal afflicted with same which comprises administering an antifungally effective amount of a compound of claim 1 sufficient for such treating or preventing. 11. The pharmaceutical composition of claim 9 wherein the mode of administration is oral or parenteral. |